Wockhardt has launched the Wockhardt Antibiotic Academy, a scientific learning platform aimed at strengthening dialogue
Wockhardt Ltd today announced that the Central Drugs Standard Control Organisation (CDSCO) has granted marketing
Wockhardt has received a favourable recommendation from the Subject Expert Committee (SEC) of the Central
Wockhardt announced that its new intravenous antibiotic Foviscu® (WCK 4282) has met the primary endpoint
Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for
The European Medicines Agency (EMA) has confirmed that Wockhardt’s antibiotic candidate WCK 5222, a combination
